C-Reactive Protein Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

C-Reactive Protein Testing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of C-Reactive Protein Testing Market

The global C-reactive protein testing market size was valued at USD 2.16 billion in 2022 and is projected to grow from USD 2.29 billion in 2023 to USD 3.29 billion by 2030, exhibiting a CAGR of 5.3% during the forecast period of 2023-2030.

The pandemic started with boosting the C-reactive protein trying out the market as it has changed to track COVID patients. Elevated CRP stages imply excessive contamination, riding extended demand for those assessments. This surge accelerated advancements in checking out technologies and extended CRP test adoption, leading to a sustained market boom and innovation.

The C-reactive protein (CRP) trying out the marketplace is pushed with the aid of numerous key factors. The increasing occurrence of infectious diseases and persistent situations, including cardiovascular sicknesses and diabetes, boosts the call for CRP checks, which can be crucial for detecting inflammation and guiding treatment. Additionally, advancements in diagnostic technologies and the growing adoption of factor-of-care testing beautify the accessibility and accuracy of CRP trying.

The C-Reactive Protein (CRP) trying out marketplace is seeing measured growth, with boom estimates starting from 1.8% to 6.9%. A key fashion is the upward thrust of excessive-sensitivity CRP (hs-CRP) tests, presenting an extra correct measure of irritation for advanced disease detection.Furthermore, developing awareness of continual illnesses and a focus on early intervention are riding CRP checking out for monitoring and timely treatment.The development of quicker and portable CRP exams may want to similarly extend trying out alternatives past hospitals and clinics.

Comprehensive Analysis of C-Reactive Protein Testing Market

The C-Reactive Protein (CRP) trying out marketplace is segmented with the aid of product, assay kind, detection variety, putting, and end consumer. By product, the marketplace consists of reagents & kits, which held the most important percentage in 2022 because of rising patient numbers and innovative product services, and devices, which might be expected to develop notably with increased regulatory approvals. By assay type, immunoturbidimetric assays dominated due to sizable product use and lively research, while ELISA and CLIA assays also maintain large marketplace shares. Detection range segmentation includes traditional CRP, driven with the aid of the superiority of persistent sicknesses, and hs-CRP, used for predicting cardiovascular risks. By setting, the laboratory trying out leads due to its precision, with factor-of-care (POC) trying out growing rapidly due to its comfort and regulatory approvals. Lastly, through stop consumer, diagnostic laboratories preserve the biggest market proportion because of expanded recognition and trying out for continual illnesses, even as hospitals and clinics are predicted to see a full-size boom due to rising health facility visits and stays.

The North American region led the C-reactive protein testing market by benefitting a size of USD 750 million in 2023 due to the excessive prevalence of persistent sicknesses inside the U.S., the provision of innovative products, and a robust recognition of scientific studies in the vicinity, the marketplace is poised for full-size growth.

The leading players in the C-Reactive Protein (CRP) testing market significantly influence its growth trajectory and set industry standards. These key players, including Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthcare Private Limited (Germany), Quest Diagnostics Incorporated (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Getein Biotech, Inc. (China), Randox Laboratories Ltd. (U.K.), BODITECH MED, INC. (Republic of Korea), and LumiraDx (U.K.), contribute to a competitive landscape, driving innovation and market advancement.

In February 2023, Qlife Holding AB introduced the Egoo CRP take a look at in Sweden. This preliminary release changed into a tender-launch, with plans to ultimately observe for the CE mark.

Segmentation Table

Attribute Details

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 5.3% from 2023-2030

Unit Value (USD billion)

Segmentation By Product, Assay Type, Detection Range, Setting, End User, and Region

By Product Reagents & Kits

Instruments

By Assay Type Chemiluminescence Immunoassay (CLIA)

Enzyme-Linked Immunosorbent Assay (ELISA)

Immunoturbidimetric Assay

Others

By Detection Range Conventional CRP

hs-CRP

By Setting

Laboratory Testing

Point-of-Care (POC) Testing

By End User Hospitals & Clinics

Diagnostic Laboratories

Others

By Region North America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country)

- U.S.

- Canada

Europe (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

- Germany

- U.K.

- France

- Italy

- Spain

- Rest of Europe

Asia Pacific (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

- China

- Japan

- India

- Australia

- Rest of Asia Pacific

Latin America (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

- Brazil

- Mexico

- Rest of Latin America

Middle East & Africa (By Product, By Assay Type, By Detection Range, By Setting, By End User, By Country/Sub-Region)

- GCC

- South Africa

- Rest of Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.